Turn Therapeutics Inc. (TTRX) Stock Price & Analysis
Turn Therapeutics Inc. (TTRX) closed at USD 11.59 on Thursday, October 15, 2026, up 4.32% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 11.11; the Oct 15, 2026 session ranged USD 11.15–11.89 on volume of 80,339 shares. Market capitalization is $351.96M, with a 52-week range of USD 2.57–16.45 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TTRX.md
Key facts (TTRX)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 25 (range 24–26).
- Total return with dividends: 1Y +105.5% vs S&P 500 +18.1%; 5Y +55.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.09, revenue estimate $0K.
Analysts (TTRX)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 25 (low 24, high 26).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | LUCID CAPITAL MARKETS | Initiated | Buy | $24 |
| 2026-09-14 | WBB Securities | Downgrade | Hold → Sell | $10 |
Total return (dividends reinvested) (TTRX)
| 1Y (from 2025-10-16) | 5Y (from 2025-10-06) | |
|---|---|---|
| Total return | +105.5% | +55.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +106.0% | +53.9% |
| Volatility (annualized) | 99.8% | 103.4% |
| Max drawdown | -52.0% (Oct 2025→Nov 2025) | -63.2% (Oct 2025→Dec 2025) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 11.59 |
|---|---|
| Change | ▲ 4.32% (up) |
| Previous Close | USD 11.11 |
| Open | USD 11.16 |
| Day Range | USD 11.15 – 11.89 |
| 52-Week Range | USD 2.57 – 16.45 |
| Volume | 80,339 shares |
| Market Cap | $351.96M |
| Exchange | NGM |
Technical Analysis (TTRX)
Nexqual's technical model rates TTRX "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49 (neutral) |
| vs SMA50 | Below (USD 11.59) |
| MACD | -0.22 (negative) |
Analyst Ratings (TTRX)
Wall Street analysts rate TTRX "Buy" based on 2 analysts, with a mean price target of USD 25 (range USD 24–26), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 25 |
| High Target | USD 26 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (TTRX)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.02 ▼ miss |
| 2026-03-31 | USD -0.04 vs est -0.02 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (TTRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -686.28% |
| Debt / Equity | 8.91 |
| Current Ratio | 1.19 |
| Total Cash | $10.29M |
| Total Debt | $6.12M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (TTRX)
Nexqual rates Turn Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $10M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$4M (TTM) |
| Efficiency | Critical — ROE -686%, ROA -50.3% |
Ownership (TTRX)
| Insider Ownership | +53.88% |
|---|---|
| Institutional Ownership | +3.82% |
| Shares Outstanding | 30.37M |
| Float | 10.83M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (TTRX)
Turn Therapeutics Inc. is led by Bradley E. Burnam (age 45), Founder, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Founder, CEO & Director | Bradley E. Burnam (age 45) |
|---|---|
| Interim CFO, VP of Finance & Chief Accounting Officer | Zuraiz Chaudhary (age 29) |
| Chief Medical Officer & Director | Neilesh Shailesh Ghodadra (age 44) |
| Chief Scientific Officer | Robert R. Redfield (age 73) |
Major Backers & Investors (TTRX)
Notable institutional backers of Turn Therapeutics Inc. include SteelPeak Wealth, LLC, IEQ Capital, LLC, Ddfg, Inc , according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SteelPeak Wealth, LLC | 0.84% |
| IEQ Capital, LLC | 0.76% |
| Ddfg, Inc | 0.36% |
| Wellington Management | 0.22% |
| Millennium Management | 0.2% |
| Aaron Wealth Advisors LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.49% |
| BlackRock | 0.26% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt